Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Synaptogenix, Inc. SNPX
$0.78
На 18:05, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
5921073.00000000
-
week52high
8.75
-
week52low
0.70
-
Revenue
0
-
P/E TTM
-4
-
Beta
1.59688100
-
EPS
-0.77000000
-
Last Dividend
0.00000000
-
Next Earnings Date
12 мая 2023 г. в 04:00
Описание компании
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | 12 апр 2022 г. | |
| Maxim Group | Hold | Buy | 19 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| TUCHMAN ALAN J | D | 33000 | 27000 | 16 дек 2022 г. |
| Bernstein Bruce | D | 27578 | 22500 | 16 дек 2022 г. |
| Alkon Daniel L. | D | 35546 | 19688 | 16 дек 2022 г. |
| SCHECHTER JONATHAN | D | 28500 | 20250 | 16 дек 2022 г. |
| Silverman Joshua | D | 38238 | 19012 | 16 дек 2022 г. |
| WEINSTEIN ROBERT | D | 33198 | 27000 | 16 дек 2022 г. |
| Singer William S. | D | 33000 | 27000 | 16 дек 2022 г. |
| TUCHMAN ALAN J | A | 68850 | 68850 | 15 ноя 2022 г. |
| Bernstein Bruce | A | 75000 | 75000 | 15 ноя 2022 г. |
| Alkon Daniel L. | A | 75000 | 75000 | 15 ноя 2022 г. |
Новостная лента
Why Is Synaptogenix (SNPX) Stock Plummeting 70% Today?
InvestorPlace
16 дек 2022 г. в 15:30
Clinical-stage biopharmaceutical firm Synaptogenix (NASDAQ: SNPX ) demonstrated the harsh pitfalls associated with innovative medicine. Following the disclosure of disappointing results for its Phase 2 study involving the treatment of advanced Alzheimer's disease, SNPX stock dropped 70% on Friday morning, extending losses to around 74% in the late afternoon.
Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be
Seeking Alpha
09 дек 2022 г. в 11:50
Synaptogenix has announced a readout of a Phase 2 randomized placebo-controlled trial in Alzheimer's disease for the current quarter. Preclinical work showed that its drug candidate Bryostatin-1 has some effect, and has a unique mechanism of action.
Synaptogenix Announces Corporate Update Conference Call
PRNewsWire
21 июл 2022 г. в 09:15
NEW YORK , July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26 th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon.
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit
PRNewsWire
29 мар 2022 г. в 09:15
NEW YORK , March 29, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present at the Hanson Wade 10th Annual Neurodegenerative Drug Development Summit on Tuesday, March 29 th at 2pm ET. The presentation is entitled, "Bryostatin Targets Restoration of Synaptic Wiring in Alzheimer's Degeneration.
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum
PRNewsWire
22 мар 2022 г. в 09:15
NEW YORK , March 22, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, announced today that Dr. Daniel Alkon, the Company's President and Chief Scientific Officer, will present a "Spotlight Showcase" of Synaptogenix under the title "Regenerative Therapeutics" on Tuesday, March 22nd at 8am ET. "Recently reported consolidated results of Synaptogenix Phase 2 clinical trial patients showed significant, persistent improvement of the cognitive psychometric Severe Impairment Battery (SIB) scores, over baseline, in a placebo-controlled publication on Bryostatin for advanced AD patients (Thompson, Tuchman, and Alkon, Journal Alzheimer's disease).